Severe Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms Overlap Syndrome Treated with Benralizumab: A Case Report

Felix K Zeller; Patrick R Bader; Mirjam C Nägeli; Philipp K Buehler; Reto A Schuepbach

doi:10.1159/000525752

Severe Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms Overlap Syndrome Treated with Benralizumab: A Case Report

Case Rep Dermatol. 2022 Jul 14;14(2):203-209. doi: 10.1159/000525752. eCollection 2022 May-Aug.

Authors

Felix K Zeller¹, Patrick R Bader¹, Mirjam C Nägeli², Philipp K Buehler¹, Reto A Schuepbach¹

Affiliations

¹ Institut für Intensivmedizin, Universitätsspital Zürich, Zürich, Switzerland.
² Dermatologische Klinik, Universitätsspital Zürich, Zürich, Switzerland.

Abstract

TEN/DRESS overlap syndrome can be difficult to diagnose, especially if it is masked by comorbidities in critically ill patients in intensive care units. The existing therapy for the two conditions is also a major challenge for the treating team. A possible alternative, especially for refractory cases, is benralizumab as an IL-5-receptor alpha-chain-specific humanized monoclonal antibody (IgG1k). We are able to show a successful treatment in this case report.

Keywords: Benralizumab; Drug reaction with eosinophilia and systemic symptoms; IL-5 blocker; Toxic epidermal necrolysis.

Publication types

Case Reports